Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 5/20 | 0.34 |
| ▸ | DRD1 | P21728 | 5/20 | 0.34 |
| ▸ | DRD4 | P21917 | 5/20 | 0.34 |
| ▸ | DRD5 | P21918 | 5/20 | 0.34 |
| ▸ | DRD3 | P35462 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PPOX | P50336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16883336 | 0.87 | DRD2 (0.32) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL4834748 | 0.85 | — | — | |
| SCHEMBL11951413 | 0.82 | CA2 (0.33) | — | |
| SCHEMBL12333680 | 0.81 | ALDH1A1 (0.39) | ALDH1A1KMT2ALMNAHTT | |
| SCHEMBL13098317 | 0.80 | — | — | |
| SCHEMBL4831836 | 0.79 | — | — | |
| SCHEMBL19055991 | 0.77 | DRD2 (0.31) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL20176706 | 0.76 | POLB (0.44) | ALDH1A1KMT2A | |
| SCHEMBL11941653 | 0.76 | ALDH1A1 (0.38) | ALDH1A1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL111659 | 0.76 | DRD2 (0.31) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200225599-A1 | LIQUID DEVELOPER AND METHOD FOR MANUFACTURING LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2020-07-16 | — | — | US | disclosed |
| US-10545424-B2 | Liquid developer and method of producing liquid developer | CANON KABUSHIKI KAISHA (JP) | 2020-01-28 | — | — | US | disclosed |
| US-10423084-B2 | Method for producing liquid developer | CANON KABUSHIKI KAISHA (JP) | 2019-09-24 | — | — | US | disclosed |
| US-20190271929-A1 | LIQUID DEVELOPER AND METHOD FOR MANUFACTURING LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2019-09-05 | — | — | US | disclosed |
| US-20190155180-A1 | METHOD FOR PRODUCING LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2019-05-23 | — | — | US | disclosed |
| US-20190094734-A1 | LIQUID DEVELOPER AND METHOD OF PRODUCING LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2019-03-28 | — | — | US | disclosed |
| US-10175597-B2 | Liquid developer and method of producing same | CANON KABUSHIKI KAISHA (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20180143546-A1 | METHOD FOR PRODUCING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2018-05-24 | — | — | US | disclosed |
| US-20180143546-A1 | METHOD FOR PRODUCING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2018-05-24 | — | — | US | disclosed |
| US-9971268-B2 | Curable liquid developer having a cationically polymerizable liquid monomer with a monofunctional vinyl ether compound | CANON KABUSHIKI KAISHA (JP) | 2018-05-15 | — | — | US | disclosed |
| US-20160349653-A1 | ULTRAVIOLET-CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2016-12-01 | — | — | US | disclosed |
| US-20160349653-A1 | ULTRAVIOLET-CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2016-12-01 | — | — | US | disclosed |
| US-20160349651-A1 | ULTRAVIOLET-CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2016-12-01 | — | — | US | disclosed |
| US-20160349655-A1 | CURABLE LIQUID DEVELOPER AND IMAGE-FORMING METHOD USING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2016-12-01 | — | — | US | disclosed |
| US-20160349655-A1 | CURABLE LIQUID DEVELOPER AND IMAGE-FORMING METHOD USING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2016-12-01 | — | — | US | disclosed |
| EP-3098659-A1 | CURABLE LIQUID DEVELOPER AND IMAGE-FORMING METHOD USING CURABLE LIQUID DEVELOPER | Canon Kabushiki Kaisha (JP) | 2016-11-30 | — | — | EP | disclosed |
| WO-2016171284-A1 | CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016111380-A1 | ULTRAVIOLET CURABLE LIQUID COMPOSITION, ULTRAVIOLET CURING INKJET INK, ULTRAVIOLET CURING WET ELECTROPHOTOGRAPHIC LIQUID DEVELOPER, ULTRAVIOLET CURING ELECTROSTATIC INKJET INK, AND IMAGE FORMING METHOD USING THEREOF | CANON KABUSHIKI KAISHA (JP) | 2016-07-14 | — | — | WO | disclosed |
| US-20150192875-A1 | ULTRAVIOLET-CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2015-07-09 | — | — | US | disclosed |
| US-20150192875-A1 | ULTRAVIOLET-CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10175597-B2 | Liquid developer and method of producing same | AUP1, RCC1, CBR1 | ALDH1A1 1142/4885DRD2 3948/4885DRD1 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.